IP Library Granted Patent US 12,194,080
Granted Patent B2
US 12,194,080 · App. 15/770,648 · Granted Jan 14, 2025

Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids

Inventors: Bruce M. Spiegelman (Waban, MA); Jonathan Z. Long (Menlo Park, CA)
Assignee: Dana-Farber Cancer Institute, Inc.
A61K38/50A61P3/10C12N9/80C12Q1/44G01N33/502C12Y305/01014G01N2800/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,080
App. No.
15/770,648
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using PM20D1 and N-lipidated amino acids.

Claims (8)

1. A method for decoupling mitochondrial respiration in a cell comprising contacting the cell with an agent that increases expression and/or activity of PM20D1 polypeptide comprising the sequence of SEQ ID NO: 2, wherein the step of contacting occurs in vitro, thereby decoupling mitochondrial respiration in the cell.

2. The method of claim 1 , wherein the agent is selected from the group consisting of a nucleic acid molecule encoding the PM20D1 polypeptide and the PM20D1 polypeptide.

3. The method of claim 1 , wherein the cell is selected from the group consisting of fibroblasts, adipoblasts, preadipocytes, adipocytes, white adipocytes, brown adipocytes, and beige adipocytes.

4. The method of claim 2 , further comprising contacting the cell with an additional agent that increases decoupled mitochondrial respiration in the cell.

5. The method of claim 2 , wherein the step of contacting occurs in vivo.

6. The method of claim 2 , wherein the step of contacting occurs in vitro.

7. The method of claim 2 , wherein the cell is selected from the group consisting of fibroblasts, adipoblasts, preadipocytes, adipocytes, white adipocytes, brown adipocytes, and beige adipocytes.

8. The method of claim 1 , further comprising contacting the cell with an additional agent that increases decoupled mitochondrial respiration in the cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 4, 2022
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061883/0024 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2019
From: SPIEGELMAN, BRUCE M.; LONG, JONATHAN Z.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 049486/0893 →
Continuity (5)
Provisional Application 62248007 · Oct 29, 2015
Provisional Application 62248365 · Oct 30, 2015
Provisional Application 62355120 · Jun 27, 2016
Provisional Application 62395735 · Sep 16, 2016
Related Publication 20210106661A1 · Apr 15, 2021
References Cited (27)
US 7541359B2 · Apodaca et al. · 2009 [cited by applicant]
US 20080003673A1 · Abuin et al. · 2008 [cited by applicant]
WO WO2007100722A2 · 2007 [cited by applicant]
WO WO2012030983A2 · 2012 [cited by applicant]
WO WO2013142571A2 · 2013 [cited by applicant]
Simmons and Michels (2015) “Type 1 diabetes: A predictable disease”, World Journal of Diabetes, 6(3): 380-90. (Year: 2015). [cited by examiner]
Shortle (2009) “One sequence plus one mutation equals two folds”, Proceedings of the National Academy of Science, USA., 106(50): 21011-12. (Year: 2009). [cited by examiner]
Roder, et al. (2016) “Pancreatic regulation of glucose homeostasis”, Experimental & Molecular Medicine, 48: e219, 19 pages long. (Year: 2016). [cited by examiner]
Winzell and Ahren (2004) “The High-Fat Diet-Fed Mouse: A Model for Studying Mechanisms and Treatment of Impaired Glucose Tolerance and Type 2 Diabetes”, Diabetes, 53(S3): S215-19. (Year: 2014). [cited by examiner]
Casal and Haskins (2006) “Large animal models and gene therapy”, European Journal of Human Genetics, 14: 266-72. (Year: 2006 ). [cited by examiner]
Long, et al. (2016) “The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria” Cell, 166: 424-35. (Year: 2016). [cited by examiner]
Gomez-Úriz et al., “Obesity and ischemic stroke modulate the methylation levels of KCNQ1 in white blood cells,” human molecular genetics, 24(5):1432-1440 (2015). [cited by applicant]
Larrick et al., “Uncoupling mitochondrial respiration for diabesity,” Rejuvenation research, 19(4):337-340 (2016). [cited by applicant]
Long et al., “The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria,” Cell, 166(2):424-435 (2016). [cited by applicant]
Partial European Search Report and Written Opinion received for EP Patent Application No. EP16860861 mailed Mar. 8, 2019. [cited by applicant]
Smorlesi et al., “The adipose organ: white-brown adipocyte plasticity and metabolic inflammation,” Obesity Reviews, 13:83-96 (2012). [cited by applicant]
Bab et al., “Skeletal Lipidomics: Regulation of Bone Metabolism by Fatty Acid Amide Family,” Brit J Pharmacol, 163(7): 1441-1446 (2011). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US/16/59289 mailed Apr. 12, 2017. [cited by applicant]
Smoum et al., “Oleoyl Serine, an Endogenous N-acyl Amide, Modulates Bone Remodeling and Mass,” P Natl Acad Sci USA, 107(41): 17710-17715 (2010). [cited by applicant]
Wang et al., “N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated with Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte,” Biochem Bioph Res Co, 466(3): 438-443 (2015). [cited by applicant]
Extended European Search Report and Written Opinion received for EP Patent Application No. EP16860861 mailed May 21, 2019. [cited by applicant]
Gomez-Uriz et al., “Obesity and ischemic stroke modulate the methylation levels of KCNQ1 in white blood cells,” Human Mol Genet 24(5):1432-1440 (2014). [cited by applicant]
Han et al., “Quantitative LC-MS/MS analysis of arachidonyl amino acids in mouse brain with treatment of FAAH inhibitor,” Analyt Biochem 432(2):74-81 (2013). [cited by applicant]
Hanus et al., “N-Acyl amino acids and their impact on biological processes: N-acyl amino acids,” Biofact 40(4):381-388 (2014). [cited by applicant]
Huang et al., “Identification of a new class of molecules the arachidonyl amino acids, and characterization of one member that inhibits pain,” J Bio Chem 276(46):42639-42644 (2001). [cited by applicant]
Ikeda et al., “Identification of N-arachidonylglycine, U18666A, and 4-androstene-3,17-dione as novel insulin Secretagogues,” Biochem Biophys Res Comm 333(3):778-786 (2005). [cited by applicant]
Connor et al., “N-Acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets”, British journal of pharmacology 160(8): 1857-1871 (2010). [cited by applicant]